JP2015210268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015210268A5 JP2015210268A5 JP2015087291A JP2015087291A JP2015210268A5 JP 2015210268 A5 JP2015210268 A5 JP 2015210268A5 JP 2015087291 A JP2015087291 A JP 2015087291A JP 2015087291 A JP2015087291 A JP 2015087291A JP 2015210268 A5 JP2015210268 A5 JP 2015210268A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- axitinib
- subject
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 67
- 206010028980 Neoplasm Diseases 0.000 claims 40
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 30
- 229960003005 axitinib Drugs 0.000 claims 30
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 27
- 102100025136 Macrosialin Human genes 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 238000003364 immunohistochemistry Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 238000000018 DNA microarray Methods 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 238000010240 RT-PCR analysis Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000010191 image analysis Methods 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000013388 immunohistochemistry analysis Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983951P | 2014-04-24 | 2014-04-24 | |
| US61/983,951 | 2014-04-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015210268A JP2015210268A (ja) | 2015-11-24 |
| JP2015210268A5 true JP2015210268A5 (https=) | 2018-05-31 |
| JP6603474B2 JP6603474B2 (ja) | 2019-11-06 |
Family
ID=53398149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015087291A Expired - Fee Related JP6603474B2 (ja) | 2014-04-24 | 2015-04-22 | 癌治療 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20170184602A1 (https=) |
| EP (1) | EP3134119B1 (https=) |
| JP (1) | JP6603474B2 (https=) |
| KR (1) | KR101943177B1 (https=) |
| CN (1) | CN106233143B (https=) |
| AR (1) | AR100169A1 (https=) |
| AU (3) | AU2015249513A1 (https=) |
| BR (1) | BR112016024143A2 (https=) |
| CA (1) | CA2946362C (https=) |
| CY (1) | CY1120731T1 (https=) |
| DK (1) | DK3134119T3 (https=) |
| ES (1) | ES2691213T3 (https=) |
| HU (1) | HUE040167T2 (https=) |
| IL (1) | IL247859B (https=) |
| MX (1) | MX375794B (https=) |
| PL (1) | PL3134119T3 (https=) |
| PT (1) | PT3134119T (https=) |
| RU (1) | RU2651469C1 (https=) |
| SG (1) | SG11201607918TA (https=) |
| SI (1) | SI3134119T1 (https=) |
| TR (1) | TR201815682T4 (https=) |
| TW (1) | TWI568439B (https=) |
| WO (1) | WO2015162532A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6945199B2 (ja) | 2017-05-19 | 2021-10-06 | 国立大学法人山口大学 | アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法 |
| US12116635B2 (en) | 2018-07-12 | 2024-10-15 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US12174192B2 (en) | 2018-07-12 | 2024-12-24 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US10586164B1 (en) | 2018-10-15 | 2020-03-10 | AIble Inc. | Interface for visualizing and improving model performance |
| US11409549B2 (en) | 2018-10-15 | 2022-08-09 | AIble Inc. | Interface for generating models with customizable interface configurations |
| US10936768B2 (en) * | 2018-10-15 | 2021-03-02 | Aible, Inc. | Interface for visualizing and improving model performance |
| US20220390456A1 (en) * | 2019-10-17 | 2022-12-08 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| JP2025518482A (ja) * | 2022-05-11 | 2025-06-17 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | 膵臓癌および２型糖尿病のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 |
| EP4522991B1 (en) * | 2022-05-11 | 2026-04-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of bmmf1 rep protein as diagnostic marker for lung cancer |
| EP4562058A1 (en) * | 2022-07-28 | 2025-06-04 | The Board of Regents of the University of Oklahoma | Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2542656A1 (en) | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | Qrt-pcr assay system for gene expression profiling |
| ES2636470T3 (es) * | 2004-04-09 | 2017-10-05 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| WO2007047955A2 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| US20070128636A1 (en) * | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| KR20090046893A (ko) * | 2006-07-28 | 2009-05-11 | 노파르티스 아게 | 흑색종에서 치료학적 반응에 대한 조기 지표로서의 흑색종 억제 활성 (ｍｉａ) 단백질의 용도 |
| WO2008066755A2 (en) * | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
| NZ597655A (en) * | 2009-07-08 | 2013-05-31 | Worldwide Innovative Network | Method for predicting efficacy of drugs in a patient |
| AU2010297344A1 (en) * | 2009-09-17 | 2012-02-23 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| US7736861B1 (en) * | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| JP2014503500A (ja) * | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
| JP6092880B2 (ja) * | 2011-10-04 | 2017-03-08 | インヴァイヴィス ファーマスーティカルズ インコーポレーテッドＩｎｖｉｖｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 抗プロゲスチン感受性腫瘍を特定および治療する方法ならびに系 |
| WO2013106765A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
-
2015
- 2015-04-16 DK DK15729222.8T patent/DK3134119T3/en active
- 2015-04-16 PT PT15729222T patent/PT3134119T/pt unknown
- 2015-04-16 MX MX2016013910A patent/MX375794B/es active IP Right Grant
- 2015-04-16 CN CN201580021401.8A patent/CN106233143B/zh not_active Expired - Fee Related
- 2015-04-16 RU RU2016140271A patent/RU2651469C1/ru active
- 2015-04-16 AU AU2015249513A patent/AU2015249513A1/en not_active Abandoned
- 2015-04-16 ES ES15729222.8T patent/ES2691213T3/es active Active
- 2015-04-16 BR BR112016024143A patent/BR112016024143A2/pt not_active Application Discontinuation
- 2015-04-16 CA CA2946362A patent/CA2946362C/en not_active Expired - Fee Related
- 2015-04-16 US US15/305,066 patent/US20170184602A1/en not_active Abandoned
- 2015-04-16 TR TR2018/15682T patent/TR201815682T4/tr unknown
- 2015-04-16 EP EP15729222.8A patent/EP3134119B1/en not_active Not-in-force
- 2015-04-16 KR KR1020167029131A patent/KR101943177B1/ko not_active Expired - Fee Related
- 2015-04-16 SG SG11201607918TA patent/SG11201607918TA/en unknown
- 2015-04-16 SI SI201530426T patent/SI3134119T1/sl unknown
- 2015-04-16 WO PCT/IB2015/052796 patent/WO2015162532A1/en not_active Ceased
- 2015-04-16 PL PL15729222T patent/PL3134119T3/pl unknown
- 2015-04-16 HU HUE15729222A patent/HUE040167T2/hu unknown
- 2015-04-22 JP JP2015087291A patent/JP6603474B2/ja not_active Expired - Fee Related
- 2015-04-23 TW TW104113043A patent/TWI568439B/zh not_active IP Right Cessation
- 2015-04-23 AR ARP150101225A patent/AR100169A1/es unknown
-
2016
- 2016-09-16 IL IL247859A patent/IL247859B/en active IP Right Grant
-
2018
- 2018-05-03 AU AU2018203086A patent/AU2018203086A1/en not_active Abandoned
- 2018-10-05 CY CY181101033T patent/CY1120731T1/el unknown
-
2019
- 2019-03-01 US US16/290,827 patent/US20190331687A1/en not_active Abandoned
-
2020
- 2020-01-13 AU AU2020200237A patent/AU2020200237A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015210268A5 (https=) | ||
| Jenkins et al. | Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer | |
| Reckamp et al. | A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma | |
| Douillard et al. | Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status | |
| ES2726650T5 (en) | Methods of monitoring immunosuppressive therapies in a transplant recipient | |
| Ishii et al. | Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples | |
| Chundong et al. | Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis | |
| JP2016513094A5 (https=) | ||
| JP2018525994A5 (https=) | ||
| Payne et al. | Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma | |
| JP2017512491A5 (https=) | ||
| McEvoy et al. | Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies | |
| JP2016500110A5 (https=) | ||
| JP2016537010A5 (https=) | ||
| Komatsubara et al. | Circulating tumor DNA as a liquid biopsy: current clinical applications and future directions. | |
| Kim et al. | Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer | |
| Liu et al. | Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study | |
| JP2018527886A5 (https=) | ||
| JP2022500504A5 (https=) | ||
| Wang et al. | Association between computed tomographic features and Kirsten rat sarcoma viral oncogene mutations in patients with stage I lung adenocarcinoma and their prognostic value | |
| JP2016515141A5 (https=) | ||
| Genovesi et al. | Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma | |
| TW201926094A (zh) | 三陰性乳癌的次分類及方法 | |
| Torricelli et al. | Genomic analysis in short-and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy | |
| Lin et al. | Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer |